Wan Feng Ting

RenBio, Inc. is a preclinical biotechnology company based in New York, NY. The company is focused on developing novel antiviral antibody therapeutics and a next-generation antibody delivery platform. RenBio's lead compound, rb-100, is a SARS-CoV-2 bispecific antibody that has demonstrated robust antiviral activity against emerging and evolving SARS-CoV-2 variants. The company is also developing a revolutionary, next-generation nucleic acid-based antibody delivery platform called Myo (Make Your Own) Technology™. RenBio was co-founded by David D. Ho, a world-renowned HIV expert and founding scientific director of the Aaron Diamond AIDS Research Center, and Yaoxing Huang, an associate professor of medical sciences at Columbia University Vagelos College of Physicians and Surgeons. The company has received non-dilutive financing from the Defense Advanced Research Projects Agency (DARPA), the Bill and Melinda Gates Foundation, and MedImmune (now AstraZeneca).